News
/news

Earli develops cancer-related biotechnology by designing cancer-activated genetic switches for immune therapies.
earli.comCrawled Oct 1, 2026
Earli’s mission is to make cancer a benign experience,by catching and curing it early.
Earli’s mission is to make cancer a benign experience by forcing it to reveal and kill itself.
Earli, a biotech company backed by $105 million across two funding rounds, is engineering **Cancer-Activated Promoters**—molecular switches triggered by cancer-specific transcription factors. These promoters reprogram tumor cells to produce therapeutic agents in situ. Co-founders Cyriac Roeding (CEO) and David Suhy (CSO) highlight how AI accelerates the design and validation of these systems for clinical translation. The company targets an **Investigational New Drug (IND) filing** in late 2026 or early 2027.
Earli uses programmable genetic constructs to engineer cancer cells into self-destructing. The approach targets tumors by exploiting their own biology, potentially offering a new precision therapy method. Cyriac Roeding highlights this strategy as a novel way to combat malignancies internally.
Three founders, united by the loss of a child to cancer, launched a startup focused on leveraging cutting-edge technology to combat and treat the disease. Their company has secured $60 million in funding to advance research and develop innovative solutions in pediatric oncology. The founders combine personal motivation with technical expertise to drive progress in cancer treatment.
Earli, a Redwood City-based biotech startup, partners with Accenture to advance its **‘synthetic biopsy’ platform**, which programs cancer cells to self-destruct and expose early-stage tumors. The technology leverages cancer’s own mechanisms to detect and eliminate malignant cells before symptoms appear. Earli’s approach builds on research inspired by Siddhartha Mukherjee’s *The Emperor of All Maladies*, targeting a critical gap in early cancer intervention.
Earli Detection showcases a screening platform at AACR 2024 that uses synthetic biomarkers to highlight cancer-dysregulated pathways. The technology targets response elements activated by malignant tumors, potentially improving early cancer detection. The approach leverages engineered biological signals to reveal hidden malignancies.